- Home
- ADIL vs VIVS Comparison
ADIL vs VIVS Comparison
Compare ADIL & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- VIVS
- Stock Information
- Founded
- ADIL 2010
- VIVS 2007
- Country
- ADIL United States
- VIVS United States
- Employees
- ADIL N/A
- VIVS N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADIL Health Care
- VIVS Health Care
- Exchange
- ADIL Nasdaq
- VIVS Nasdaq
- Market Cap
- ADIL 3.9M
- VIVS 4.2M
- IPO Year
- ADIL 2018
- VIVS N/A
- Fundamental
- Price
- ADIL $0.34
- VIVS $1.45
- Analyst Decision
- ADIL Strong Buy
- VIVS
- Analyst Count
- ADIL 1
- VIVS 0
- Target Price
- ADIL $8.00
- VIVS N/A
- AVG Volume (30 Days)
- ADIL 22.2M
- VIVS 64.3K
- Earning Date
- ADIL 08-12-2025
- VIVS 07-07-2025
- Dividend Yield
- ADIL N/A
- VIVS N/A
- EPS Growth
- ADIL N/A
- VIVS N/A
- EPS
- ADIL N/A
- VIVS N/A
- Revenue
- ADIL N/A
- VIVS $144,000.00
- Revenue This Year
- ADIL N/A
- VIVS $42.38
- Revenue Next Year
- ADIL N/A
- VIVS $15.42
- P/E Ratio
- ADIL N/A
- VIVS N/A
- Revenue Growth
- ADIL N/A
- VIVS 32.11
- 52 Week Low
- ADIL $0.22
- VIVS $1.41
- 52 Week High
- ADIL $3.00
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- ADIL 50.21
- VIVS N/A
- Support Level
- ADIL $0.22
- VIVS N/A
- Resistance Level
- ADIL $0.27
- VIVS N/A
- Average True Range (ATR)
- ADIL 0.08
- VIVS 0.00
- MACD
- ADIL -0.01
- VIVS 0.00
- Stochastic Oscillator
- ADIL 53.15
- VIVS 0.00
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.